The information below contains relevant published literature and is intended for veterinarians and researchers
If you are a veterinarian or researcher interested in collaborating with us, please contact us.
Peer Reviewed Publications For
Pawsni’s Ingredients
Compendium of F. prausnitzii
One of the most clinically significant and abundant
commensal bacteria in the gut microbiome
F. prausnitzii paraprobiotics.
What does the research tell us?
Pawsni™ contains five natural ingredients, all carefully selected to improve metabolic health and digestion. However, F. prausnitzii is its the primary ingredient. F. prausnitzii is one of the most abundant beneficial bacteria in the gut of all animals (including humans!), making up 3-5% of a healthy microbiome. Like many beneficial gut bacteria, F. prausnitzii is an obligate anaerobe, meaning it will not survive in the presence of oxygen.
The F. prausnitzii strains used to make Pawsni were discovered by researchers at Cornell University in 2015, followed by 5 additional years of Pawsni researchers perfecting it’s growth and performing trials to determine its metabolic benefits.
While performing research funded by the National Science Foundation to evaluate new compounds that treat metabolic diseases like prediabetes and diabetes, Pawsni’s scientists discovered that metabolites expressed from their strains and the killed cell components (paraprobiotics) significantly reduced blood glucose and %A1C levels in multiple mouse trials. In many cases, fasting blood glucose levels of prediabetic mice returned to healthy levels after just 2 weeks of administration (see publication here). After patenting these findings, the team joined forces with animal health experts to create Pawsni™ — the worlds first product to support Metabolic Health derived from F. prausnitzii.
Pawsni combines F. prausnitzii paraprobiotics with other scientifically tested ingredients to create the only product like it in the world.
Pawsni Metabolic Health Active Ingredients
F. prausnitzii
Strains of Faecalibacterium prausnitzii and its extracts reduce blood glucose levels, percent HbA1c, and improve glucose tolerance without causing hypoglycemic side effects in diabetic and prediabetic mice.
Kallassy J, Gagnon E, Rosenberg D, Silbart LK, McManus, SA. BMJ Open Diab Res Care 2023;11:e003101
______________________
Patent: F. prausnitzii and its derivatives to treat or support health problems, including prediabetes, diabetes, and other conditions.
Patent # WO2022026873A1
______________________
Patent: Antimicrobial compounds isolated from F. prausnitzii and their use to inhibit bacterial growth or prevent bacterial infection, inhibit the virulence of bacteria such as E. coli, and to treat diseases such as irritable bowel disease, Crohn's disease, ulcerative colitis, and others.
Patent # WO2023064443A1
Faecalibacterium: a bacterial genus with promising human health applications
Rebeca Martín, David Rios-Covian, Eugénie Huillet, Sandrine Auger, Sarah Khazaal, Luis G Bermúdez-Humarán, Harry Sokol, Jean-Marc Chatel, and Philippe Langella
______________________
Faecalibacterium prausnitzii Improves Lipid Metabolism Disorder and Insulin Resistance in Type 2 Diabetic Mice.
Xuan Wenting, Ou Yijing, Chen Wenting, Huang Lishan, Wen Chuangyu, Huang Guangying, Tang Wenting, Zeng Daidi, Huang Suran, Xiao Lijuan, Li Zhongjun
Br J Biomed Sci. 2023 Mar 21;80:10794.
Pyroxidine
Effect of a Leucine/Pyridoxine Nutraceutical on Caloric Intake and Body Composition of Obese Dogs Losing Weight
Murphy M, Bartges JW, Zemel MB, Kirk CA, Witzel-Rollins A. Front Vet Sci. 2020, 25, 7, 555
______________________
The Postprandial Anti-Hyperglycemic Effect of Pyridoxine and Its Derivatives Using In Vitro and In Vivo Animal Models
Kim, H.H., Kang, Y.-R., Lee, J.-Y., Chang, H.-B., Lee, K.W., Apostolidis, E., Kwon, Y.-I. Nutrients 2018, 10, 285
Inulin
The effects of inulin supplementation of diets with or without hydrolysed protein sources on digestibility, faecal characteristics, haematology and immunoglobulins in dogs
Verlinden A, Hesta M, Hermans JM, Janssens GP.. Br J Nutr. 2006 Nov;96, 5, 936-44
______________________
Duration of Prebiotic Intake Is a Key-Factor for Diet-Induced Modulation of Immunity and Fecal Fermentation Products in Dogs. Microorganisms
Perini MP, Rentas MF, Pedreira R, Amaral AR, Zafalon RVA, Rodrigues RBA, Henríquez LBF, Zanini L, Vendramini THA, Balieiro JCC, Pontieri CFF, Brunetto MA. 2020, 8, 12, 1916.
Pet food and feed applications of inulin, oligofructose and other oligosaccharides
Flickinger EA, and Fahey Jr., GC., British Journal of Nutrition 2002, 87, Suppl. 2, S297–S300
Leucine
Effect of a Leucine/Pyridoxine Nutraceutical on Caloric Intake and Body Composition of Obese Dogs Losing Weight
Murphy M, Bartges JW, Zemel MB, Kirk CA, Witzel-Rollins A. Front Vet Sci. 2020, 25, 7, 555
______________________
Stimulation of Insulin Release in the Dog by a Nonmetabolizable Amino Acid. Comparison with Leucine and Arginine
Fajans, SS., Quibrera, R., Pek, S., Floyd, JC., Christensen, HN., Conn, JW. The Journal of Clinical Endocrinology & Metabolism, 1971, 33, 1, 35–41
Effect of L-leucine on glucose turnover in dogs
Shafeek S. Sanbar. Metabolism 1966, 15, 6, 557-565
______________________
Role of leucine and other amino acids in regulating protein metabolism in vivo
Frexes-Steed, M., Lacy, MDB, Collins, J., and Abumrad, NN. American Journal of Physiology-Endocrinology and Metabolism 1992 262:6, E925-E935
The beneficial properties of Pawsni’s five natural ingredients are all well documented and all important for establishing optimal metabolic health in cats and dogs.
It is estimated that 60% of cats and 56% of dogs were overweight or obese as of 2017. T1D is the most common type of diabetes in dogs, but as is the case with humans, incidence of T2D is rapidly increasing as well. From 2006 to 2015, canine diabetes has increased 79.7%
One of the ingredients in Pawsni is a paraprobiotic derived from F. prausnitzii and is in a class of its own—and for good reason.
F. prausnitzii is a commensal bacterium naturally found in the gastrointestinal tract of birds and mammals, including humans, cattle, pigs, swine, poultry, dogs, and cats. F. prausnitzii is a non-spore forming, anaerobic bacteria and is highly abundant microbe in the gut of animals, making up 5% of the total gut microbiota population in humans (Miquel et al., 2013). Faecalibacterium, as well as other species of bacteria, produce physiologically important molecules including peptides, fatty acids and other small molecules. Evidence supports that low levels of F. prausnitzii have been associated with diseases such as inflammatory bowel disease, colitis, type 2 diabetes, and other disorders. This evidence is supported for a multitude of animal species including poultry, dogs, cats, rodents, and humans. F. prausnitzii and its derivatives have consistently demonstrated various potential health benefits across a number of animal species, such as reduction in diarrhea, muscle growth enhancement, and general protection from inflammation. Our technology is further supported by approved and pending patents covering compositions and methods for treating a disease or condition characterized by impaired glucose metabolism in humans and animals using F. prausnitzii probiotics or compositions to inhibit bacterial growth, prevent bacterial infection, inhibit the virulence of bacteria such as E. coli.
Our scientists recently published a manuscript describing pre-clinical rodent trials including trials testing our proprietary paraprobiotic in prediabetic and mice with type 2 diabetes (see manuscript here). Trials in prediabetic and diabetic mice revealed that peroral administration of live cells or paraprobiotics and metabolites expressed from F. prausnitzii lowered fasting blood glucose levels and improved glucose tolerance compared with control mice. A similar trial resulted in lowered percent HbA1c when the same actives were administered.
Multiple groups have independently found administration of F. prausnitzii and the metabolites led to increased levels of the anti-inflammatory cytokine IL-10 in dendritic cells (Rossi et al, 2016), gut epithelial cells (Rabiei et al, 2019), as well as mouse models for Crohns disease (Sokol et al, 2008) and Colitis (Zhang et al,2014). Administration of F. prausnitzii has also been associated with increased levels of other anti-inflammatory cytokines including IL-4 (Huang et al, 2016, Rabiei et al, 2019) and TGFbeta (Zhou et al, 2018). Administration of F. prausnitzii has also been associated with reduction in expression of pro-inflammatory cytokines. F. prausnitzii administration has been shown to lead to reduction of pro-inflammatory cytokines IL-6 (Huang et al,2016, Martin et al 2015, Rabiei et al, 2019), IL-12 (Sokol et al, 2008, Rabiei et al, 2019), IL-17 ( Rabiei et al, 2019), INFalpha (Sokol et al 2008, Martin et al 2015), INFgamma (Rabiei et al, 2019), IL-23 (Zhang et al, 2014), IL-8 (Quevrain et al, 2016).